Welcome to our dedicated page for Briacell Therapeutics news (Ticker: BCTXW), a resource for investors and traders seeking the latest updates and insights on Briacell Therapeutics stock.
BriaCell Therapeutics Corp. (BCTXW) generates frequent news as a clinical-stage biotechnology company developing novel cancer immunotherapies. News about BriaCell often centers on its Bria-IMT regimen and related platforms for metastatic breast cancer, including updates from Phase 1/2, Phase 2 and pivotal Phase 3 clinical studies. Investors and observers can follow announcements on survival outcomes, safety profiles, biomarker analyses and regulatory designations related to these programs.
Recent company updates include pivotal Phase 3 trial progress in metastatic breast cancer, with information on patient screening and enrollment, interim analysis plans, and the use of overall survival as a primary endpoint. BriaCell also reports on Phase 2 survival data and biomarker findings presented at major meetings such as the San Antonio Breast Cancer Symposium, highlighting potential predictors of clinical benefit like Neutrophil-to-Lymphocyte Ratio, Delayed Type Hypersensitivity, and Th1-biased cytokine signatures.
BriaCell’s news flow further covers its Bria-OTS and Bria-OTS+ platforms, including clinical observations such as sustained complete resolution of lung metastasis in a Bria-OTS-treated metastatic breast cancer patient, and preclinical data showing rapid and durable immune activation by Bria-OTS+ candidates Bria-BRES+ and Bria-PROS+ in breast and prostate cancer models. Additional items include collaborations and pipeline expansion, such as the AI-driven small-molecule discovery partnership between BriaPro and Receptor.AI.
By following the BCTXW news page on Stock Titan, readers can review company press releases and third-party coverage related to BriaCell’s clinical milestones, scientific presentations, platform developments and strategic collaborations, all organized around this specific listed security.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) has entered a research collaboration with Harvard Medical School, led by Dr. Joan S. Brugge, to identify novel anti-cancer treatment targets. The focus will be on enhancing tumor cell response to chemotherapy and immunotherapies for lung, head and neck, cervical, and bladder cancers. Under the one-year agreement, BriaCell may negotiate licenses for any innovations developed. This partnership aims to address significant challenges in precision cancer treatments and aligns with BriaCell's strategy for developing effective cancer therapies.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) announced significant findings from a publication on its lead candidate, Bria-IMT™, for advanced breast cancer. The research, published in Recent Patents on Anti-Cancer Drug Discovery, demonstrated Bria-IMT™'s ability to rapidly destroy tumors in patients with matching HLA types, aligning with BriaCell's strategy for off-the-shelf personalized immunotherapy. Clinical data indicated tumor shrinkage and an overall survival exceeding 33 months in some patients, affirming the drug's efficacy and safety.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) has activated Hoag Memorial Hospital and re-engaged Sylvester Comprehensive Cancer Center to enhance patient enrollment in its Phase I/IIa clinical trial for Bria-IMT™ in combination with Incyte’s therapies. The addition of these sites aims to accelerate patient recruitment, as BriaCell prepares for discussions with the FDA regarding safety and efficacy data. This phase of the trial includes several active sites across the U.S., representing BriaCell's ongoing commitment to advancing immunotherapy for advanced breast cancer.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) announced that the FDA has granted Fast Track status to its lead immunotherapy candidate, Bria-IMT™, aimed at treating metastatic breast cancer. This designation allows for quicker communication with the FDA, potentially leading to earlier drug approval and patient access. BriaCell is currently enrolling patients in a Phase I/IIa clinical trial, combining Bria-IMT™ with Incyte's checkpoint inhibitor retifanlimab and immunomodulator epacadostat.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) has developed Bria-OTS™, a novel off-the-shelf personalized immunotherapy for advanced breast cancer, discussed during the AACR Annual Meeting 2022. This innovative treatment aims to match patients' HLA types using a simple saliva test, enhancing the likelihood of clinical benefits. The Bria-OTS™ therapy utilizes genetically modified cell lines to cater to over 99% of the population, accelerating treatment without complex manufacturing processes. An open-label Phase I/IIa clinical trial is anticipated to evaluate its safety and efficacy.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) has developed Bria-OTS™, an off-the-shelf personalized immunotherapy for advanced breast cancer. Currently in production at a cGMP facility, Bria-OTS™ is undergoing quality control testing in preparation for an upcoming Phase I/IIa clinical trial. Collaborating with the National Cancer Institute, BriaCell aims to optimize treatment based on patients' HLA types. The company will present details about Bria-OTS™ at the American Association for Cancer Research Annual Meeting on April 12, 2022.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) announces the recruitment of two new clinical sites for a Phase I/IIa study of its lead candidate, Bria-IMT™, combined with Incyte’s retifanlimab and epacadostat for advanced breast cancer. New sites include Atlantic Health System in New Jersey and Tranquil Clinical Research in Texas, enhancing patient access across the U.S. BriaCell emphasizes the urgent need for effective treatments in advanced breast cancer, collaborating with notable oncologists in these locations for patient care.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) has appointed immunologist Alexander Kharazi, M.D., Ph.D., to its Scientific Advisory Board. Kharazi, co-inventor of Bria-IMT™, brings over 30 years of expertise in immunotherapy, having held prominent roles in various institutions and holds multiple patents. This strategic addition is expected to enhance BriaCell’s efforts in developing targeted immunotherapies for advanced breast cancer, as noted by President & CEO Bill Williams, highlighting Kharazi’s knowledge as a significant asset.
BriaCell Therapeutics Corp. (BCTX, BCTXW) announces the appointment of Dr. Giuseppe Del Priore as Chief Medical Officer, effective immediately. He will manage clinical and regulatory aspects of ongoing and future trials, including a Phase I/IIa study of Bria-IMT™ combined with checkpoint inhibitors in advanced breast cancer patients. Dr. Del Priore brings over 25 years of oncology experience and has held leadership roles in clinical trials management. His appointment is expected to advance BriaCell's mission to provide innovative therapies for cancer patients with limited options.
BriaCell Therapeutics (BCTX, BCTXW) has been selected to present at the AACR Annual Meeting 2022, showcasing its innovative cancer immunotherapy. The company also continues its corporate buyback program, having repurchased over 1 million shares and warrants since its inception. Additionally, insiders plan to individually acquire approximately 1.59 million shares, representing 10% of the company's common shares. With approximately $52 million in cash and no debt, BriaCell aims to enhance shareholder value through these strategic initiatives.